The invention relates to a process for dehumidifying a moist gas mixture. The invention further relates to an apparatus for dehumidifying a moist gas mixture and to the use of said apparatus in the process according to the invention

The present application relates to siloxane-containing phospholipids such as the compounds of Formula I, methods of preparation, compositions and uses thereof.

##STR00001##

An oral care composition in the form of a toothpaste, tooth gel, dentifrice, tooth powder, prophy paste, mouthwash, rinse, tooth mousse, dental floss, chewing gum, soluble oral care strip or film for direct application or attachment to an oral surface, or lozenge for combating dental caries, erosion, hypersensitivity, and/or staining that includes an orally acceptable carrier and a copolymer of a first α,β-ethylenically unsaturated phosphate compound (A); and one or more α,β-ethylenically unsaturated co-monomers, at least one of which is other than an allyl-functional co-monomer, wherein (A) is an allyl phosphate compound of formula (A):
[CH.sub.2═CH—CH.sub.2—O(R.sup.1O).sub.a(R.sup.2O).sub.b].sub.xP(O)(OM).sub.3-x   (A)
wherein, R.sup.1 is a substituted or unsubstituted (C.sub.2-C.sub.4) alkylene moiety; R.sup.2 is a substituted or unsubstituted (C.sub.2-C.sub.4) alkylene moiety; M is identical or different, hydrogen, alkali metal, ammonium, protonated alkyl amine, protonated alkanolamine, or protonated basic amino acid; X is 1 or 2, a is from 1 to 20; and b is from 0 to 20. Methods for combating dental caries, erosion, hypersensitivity, and/or staining are also provided.

An additive, a non-aqueous electrolyte for a lithium secondary battery including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, an additive includes at least one compound selected from the group consisting of the compounds represented by Formula 1 and Formula 2. In some embodiments, a non-aqueous electrolyte includes a lithium salt, an organic solvent, and an additive including at least one compound selected from the group consisting of the compounds represented by Formula 1 and Formula 2.

The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas:

##STR00001##

wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.

The present invention includes compound having the following structural formula:

##STR00001##

This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.

Disclosed is a method for linkage recovery of an organic acid in an aqueous organic acid solution. The method comprises: mixing a solution with an organic acid concentration lower than 20 wt % with a specific extractant and then subjecting same to counter-current extraction so as to obtain an extract phase and a raffinate phase; and subjecting the extract phase together with a solution with an acid concentration higher than 70 wt % to an azeotropic rectification so as to recover an organic acid. When the concentration of the aqueous organic acid solution is 20 wt %-70 wt %, the aqueous organic acid solution is extracted and concentrated to make the concentration of the aqueous organic acid solution higher than 70 wt %.

The present disclosure provides a pharmaceutical preparation of a compound of formula (I) or a stereoisomer, pharmaceutically acceptable salt, or prodrug thereof. The present disclosure further provides a method for general anesthesia or sedation for mammals. Also provided are kits and manufactured products of the medicament and the pharmaceutical composition and a method for using the medicament and the pharmaceutical composition.

##STR00001##